Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
J Am Acad Dermatol ; 90(4): 798-805, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38081390

ABSTRACT

BACKGROUND: Amid a movement toward value-based healthcare, increasing emphasis has been placed on outcomes and cost of medical services. To define and demonstrate the quality of services provided by Mohs surgeons, it is important to identify and understand the key aspects of Mohs micrographic surgery (MMS) that contribute to excellence in patient care. OBJECTIVE: The purpose of this study is to develop and identify a comprehensive list of metrics in an initial effort to define excellence in MMS. METHODS: Mohs surgeons participated in a modified Delphi process to reach a consensus on a list of metrics. Patients were administered surveys to gather patient perspectives. RESULTS: Twenty-four of the original 66 metrics met final inclusion criteria. Broad support for the initiative was obtained through physician feedback. LIMITATIONS: Limitations of this study include attrition bias across survey rounds and participation at the consensus meeting. Furthermore, the list of metrics is based on expert consensus instead of quality evidence-based outcomes. CONCLUSION: With the goal of identifying metrics that demonstrate excellence in performance of MMS, this initial effort has shown that Mohs surgeons and patients have unique perspectives and can be engaged in a data-driven approach to help define excellence in the field of MMS.


Subject(s)
Skin Neoplasms , Surgeons , Humans , Skin Neoplasms/surgery , Mohs Surgery , Consensus , Benchmarking
4.
Arch Dermatol Res ; 314(6): 533-540, 2022 Aug.
Article in English | MEDLINE | ID: mdl-34132885

ABSTRACT

Cutaneous operations are generally safe procedures with minimal major risks. Excessive bleeding occasionally occurs, especially for patients taking antithrombotic medications. Conversely, stopping these medications before cutaneous surgery may increase the risk of a thromboembolic event. We aimed to synthesize the evidence regarding the risk of hemorrhage and thromboembolic events for patients undergoing cutaneous surgery while taking antithrombotic therapy. We performed a comprehensive search to identify randomized controlled trials and cohort studies that compared rates of hemorrhage and/or thromboembolic events between patients receiving antithrombotic therapy at cutaneous surgery and patients not receiving it. Odds ratio (OR) and risk difference for complications were calculated with random-effects models. Of 9214 patients taking anticoagulant or antiplatelet medications, 323 (3.5%) had hemorrhagic complications; of 21,696 control patients, 265 (1.2%) had hemorrhagic complications. Patients taking antithrombotic therapy had increased bleeding risk relative to control patients (OR 2.63 [95% CI 1.90-3.63]; P < 0.001) and an increased but less clinically important risk difference (OR 0.02 [95% CI 0.01-0.03]; P < 0.001) with high heterogeneity. No difference was observed in hemorrhage rates among patients whose antithrombotic therapy was stopped vs continued (OR 1.16 [95% CI 0.73-1.83]; P = 0.54). No difference was seen in rates of thromboembolic events among patients taking antithrombotic therapy vs control patients. However, two serious thromboembolic events were noted in a cohort of 59 patients whose antithrombotic therapy was stopped. Because of potentially devastating effects of thromboembolic events, the current accepted practice is indicated for continuation of antithrombotic therapy for patients undergoing cutaneous surgery.


Subject(s)
Fibrinolytic Agents , Thromboembolism , Anticoagulants/adverse effects , Dermatologic Surgical Procedures/adverse effects , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Hemorrhage/complications , Hemorrhage/epidemiology , Humans , Platelet Aggregation Inhibitors/adverse effects , Thromboembolism/chemically induced , Thromboembolism/epidemiology , Thromboembolism/prevention & control
5.
Dermatol Surg ; 48(2): 157-161, 2022 02 01.
Article in English | MEDLINE | ID: mdl-34889209

ABSTRACT

BACKGROUND: Limited data exist on sentinel lymph node biopsy (SLNB) for cutaneous squamous cell carcinoma (cSCC) of the head and neck. OBJECTIVE: To review the results of SLNB for patients with cSCC of the head and neck at the authors' institution. MATERIALS AND METHODS: A retrospective review was completed for patients who underwent SLNB for cSCC of the head and neck over 19 years. Patient demographics, immune status, tumor stage, total patients with positive SLNB, local recurrence, nodal recurrence, in-transit metastasis, and disease-specific death were recorded. RESULTS: Sixty patients underwent lymphoscintigraphy, and an SLN was identified in 58 patients. The mean follow-up was 3.2 years (range, 15 days-16 years). Four patients (6.9%) had a positive SLNB. All were Brigham and Women's Hospital (BWH) stage T2b tumors. Three of these patients were immunosuppressed, 3 patients underwent neck dissection, and 2 patients received adjuvant radiation. None developed local or regional recurrence. Of the 53 patients with a negative SLNB, there were 4 local recurrences, 2 in-transit metastases, and no nodal recurrences. CONCLUSION: Immunosuppressed patients with tumors BWH stage T2b or greater may be a reasonable cohort to focus future prospective studies on the utility of SLNB in cSCC of the head and neck.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Skin Neoplasms , Adult , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/surgery , Humans , Lymph Nodes/pathology , Prospective Studies , Recurrence , Retrospective Studies , Sentinel Lymph Node Biopsy , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Squamous Cell Carcinoma of Head and Neck/surgery
6.
Dermatol Surg ; 46(12): 1588-1592, 2020 12.
Article in English | MEDLINE | ID: mdl-32826600

ABSTRACT

BACKGROUND: Perioperative anxiety can negatively impact patient satisfaction and can complicate outpatient dermatologic procedures. OBJECTIVE: Evaluate adverse events associated with oral midazolam as a perioperative anxiolytic during dermatologic surgery and assess whether an enhanced monitoring approach is associated with an increased detection rate. MATERIALS AND METHODS: Five hundred cases (250 before and after change in monitoring) where patients were administered oral midazolam between July 2015 and May 2017 were retrospectively reviewed. The number of procedures, type of procedures, dose in milligrams, number of doses, major and minor adverse events, and vital signs were recorded. RESULTS: The difference in number of treatment sites, types of procedures, and total dose administered was not significant. There were minor but significant differences in the mean change in blood pressure, heart rate, respiratory rate, and Richmond Agitation and Sedation Scale score before and after the procedure but not oxygen saturation. These vital sign changes were not clinically significant. There were zero major adverse events in both groups. There were 2 patients who became transiently hypoxic. CONCLUSION: Oral midazolam administration was not associated with major adverse events including in the more intensively monitored group. This supports its use as an anxiolytic for outpatient dermatologic procedures.


Subject(s)
Ambulatory Surgical Procedures/adverse effects , Anti-Anxiety Agents/adverse effects , Anxiety/prevention & control , Dermatologic Surgical Procedures/adverse effects , Drug-Related Side Effects and Adverse Reactions/epidemiology , Midazolam/adverse effects , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Ambulatory Surgical Procedures/psychology , Anti-Anxiety Agents/administration & dosage , Anxiety/etiology , Anxiety/psychology , Dermatologic Surgical Procedures/psychology , Dose-Response Relationship, Drug , Drug Monitoring/statistics & numerical data , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Humans , Male , Midazolam/administration & dosage , Middle Aged , Patient Satisfaction , Perioperative Care/adverse effects , Perioperative Care/methods , Retrospective Studies , Treatment Outcome , Young Adult
7.
Dermatol Surg ; 46(7): 904-911, 2020 07.
Article in English | MEDLINE | ID: mdl-32079868

ABSTRACT

BACKGROUND: Few publications have addressed nasal valve (NV) insufficiency as a complication of Mohs micrographic surgery. OBJECTIVE: To comprehensively review the literature and further characterize the causes, prevalence, evaluation, and management of NV insufficiency as it relates to cutaneous oncology. MATERIALS AND METHODS: A PubMed search was completed to identify articles related to the NV in the context of Mohs micrographic surgery, cutaneous oncology, and reconstruction. RESULTS: Nasal valve insufficiency may occur during tumor removal and/or reconstruction. Defect size larger than 1 cm; location on the ala, sidewall, or alar crease; lack of structural support; and poorly planned flaps are the main risk factors for NV insufficiency. Several surgical techniques have been described to avoid and correct this complication. CONCLUSION: Nasal valve insufficiency may be an underrecognized and underreported complication of Mohs micrographic surgery. Nasal valve insufficiency may be identified with relatively simple tests. Knowledge of NV anatomy and preoperative function assessment is essential. Recognition of this potential complication and awareness of its prevention and management may decrease morbidity in patients undergoing cutaneous surgery.


Subject(s)
Mohs Surgery/adverse effects , Nose Diseases/etiology , Nose Neoplasms/surgery , Postoperative Complications/etiology , Humans , Nose Diseases/diagnosis , Nose Diseases/epidemiology , Nose Diseases/therapy , Postoperative Care , Postoperative Complications/diagnosis , Postoperative Complications/epidemiology , Postoperative Complications/therapy
9.
J Am Acad Dermatol ; 80(3): 743-748, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30287315

ABSTRACT

BACKGROUND: Little information is available to predict which patients require opioid analgesia following cutaneous surgery. When opioids are indicated, information regarding the optimal opioid agent selection and dosage is lacking. OBJECTIVE: To make recommendations for opioid prescription after cutaneous surgery. METHODS: A PubMed literature search was conducted to review the available literature. Recommendations are presented on the basis of available evidence and the opinion of the authors. RESULTS: Most patients undergoing cutaneous surgery do not require opioid analgesia. For those who do, the duration of pain warranting opioid analgesia is generally less than 36 hours. Opioid refill requests warrant a follow-up visit to ascertain the cause of ongoing pain after excisional procedures. LIMITATIONS: The recommendations are not based on prospective randomized trials. CONCLUSIONS: The presented recommendations for opioid prescription practice are derived from available evidence, recommendations, and expert opinion.


Subject(s)
Analgesics, Opioid/therapeutic use , Dermatologic Surgical Procedures/adverse effects , Pain, Postoperative/drug therapy , Drug Prescriptions , Humans , Opioid-Related Disorders/prevention & control , Pain, Postoperative/etiology , Practice Guidelines as Topic
10.
J Surg Oncol ; 118(4): 606-613, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30114337

ABSTRACT

BACKGROUND AND OBJECTIVES: To describe the patterns of failure in patients with in-transit (IT) melanoma undergoing surgical excision. METHODS: A retrospective review of patients who underwent their first IT lesion(s) resection between May 2005 and September 2014. Cumulative incidence of local failure (new lesion within 2 cm of IT resection) was estimated. Associations between clinicopathologic characteristics, local failure, and any recurrence were analyzed. RESULTS: One hundred and thirty patients presented to our institution with IT disease over the study period and met the inclusion criteria. The 2-year cumulative incidence of local failure was 19.5%. Twenty-four patients developed disease within 2 cm of the resected IT disease; however, only eight were isolated local events. Cumulative incidence of local failure and of any disease differed with respect to less than 1 year disease-free interval (DFI) from primary melanoma to first IT event, and having greater than 1 IT lesion at presentation. Incidence of local failure was not found to differ with respect to gross margin greater than 5 mm, after adjusting for DFI and greater than 1 IT lesions. CONCLUSIONS: Patients with greater than 1 IT lesion and a DFI less than 1 year are at a higher risk of failure after surgical excision of a first IT event. Very few failures were isolated local disease within 2 cm of the IT resection scar, regardless of IT excision margin.


Subject(s)
Melanoma/pathology , Melanoma/surgery , Neoplasm Recurrence, Local/epidemiology , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Surgical Procedures, Operative/adverse effects , Aged , Female , Follow-Up Studies , Humans , Incidence , Male , Margins of Excision , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/etiology , Retrospective Studies , Treatment Failure
12.
J Am Acad Dermatol ; 78(1): 141-147, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28917382

ABSTRACT

Most primary cutaneous squamous cell carcinomas are cured with surgery. A subset, however, may develop local and nodal metastasis that may eventuate in disease-specific; death. This subset has been variably termed high risk. Herein, we review; an emerging body of data on the risks of these outcomes and propose an evidence-based; risk stratification for low-, intermediate-, and high-risk tumors that takes into; account both tumor and patient characteristics. Finally, we discuss a framework for; management of these tumors on the basis of data, when available, and our; recommendations when data are sparse.


Subject(s)
Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/pathology , Lymph Nodes/pathology , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Adult , Aged , Biopsy, Needle , Carcinoma, Squamous Cell/therapy , Disease Management , Evidence-Based Medicine , Female , Humans , Immunohistochemistry , Lymph Node Excision/methods , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Invasiveness/pathology , Prognosis , Risk Adjustment , Skin Neoplasms/therapy , Survival Analysis , United States
13.
Dermatol Surg ; 43(5): 708-714, 2017 May.
Article in English | MEDLINE | ID: mdl-28178005

ABSTRACT

BACKGROUND: Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma occurring mainly in the anogenital region. Traditional management with wide local excision has shown high recurrence rates, thus Mohs micrographic surgery (MMS) has emerged as a promising treatment option. OBJECTIVE: To compare long-term outcomes after treatment with MMS or excision for primary EMPD. METHODS AND MATERIALS: Retrospective cohort review was conducted for 207 patients with EMPD treated at Mayo Clinic in Rochester, MN, between 1961 and 2012. RESULTS: Of the 25 patients treated with MMS, 19 primary tumors were included for outcome analysis, with an estimated 5-year recurrence-free survival rate of 91% (95% confidence interval [CI], 75-100) using Kaplan-Meier curve analysis. Of 158 patients treated with local excision, 124 were included for the analysis, with an estimated 5-year recurrence-free survival rate of 66% (95% CI, 56-78). The hazard ratio (HR) for association of treatment was 0.4 (95% CI, 0.10-1.65; p = .20). Estimated 5-year overall survival rates were 79% for MMS (95% CI, 61-100) and 68% for excision (95% CI, 59-78) (HR, 1.39 [95% CI, 0.69-2.82]; p = .36). CONCLUSION: Although treatment of primary EMPD with MMS versus excision did not show statistical difference, MMS demonstrated favorable long-term outcomes and was associated with a higher recurrence-free survival rate.


Subject(s)
Mohs Surgery , Paget Disease, Extramammary/surgery , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Genital Neoplasms, Male/surgery , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Recurrence, Local , Paget Disease, Extramammary/mortality , Retrospective Studies , Scrotum/surgery , Treatment Outcome , Vulvar Neoplasms/surgery
14.
Dermatol Surg ; 43(1): 98-106, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27749444

ABSTRACT

BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor with slow infiltrative growth and local recurrence if inadequately excised. OBJECTIVE: To compare long-term outcomes after Mohs micrographic surgery (MMS) and wide local excision (WLE). MATERIALS AND METHODS: Records of patients with DFSP surgically treated with WLE or MMS from January 1955 through March 2012 were retrospectively reviewed. RESULTS: Mean follow-up for patients treated with MMS (n = 67) and WLE (n = 91) was 4.8 and 5.7 years, respectively. Twenty-eight patients (30.8%) with WLE had recurrence (mean, 4.4 years), whereas only 2 (3.0%) with MMS had recurrence (1.0 and 2.6 years). Recurrence-free survival rates at 1, 5, 10, and 15 years were significantly higher with MMS (p < .001). Mean preoperative lesion sizes were similar (5-6 cm) between the 2 groups, whereas mean (standard deviation) postoperative defect sizes were 10.7 (4.3) cm and 8.8 (5.5) cm for WLE and MMS, respectively (p = .004). Primary closure was used for 73% of MMS cases, whereas WLE more commonly used flaps, grafts, or other closures (52%). Two Mohs layers typically were required for margin control. CONCLUSION: Surgical excision with meticulous histologic evaluation of all surgical margins is needed for DFSP treatment to achieve long-term high cure rates and low morbidity.


Subject(s)
Dermatofibrosarcoma/surgery , Mohs Surgery , Neoplasm Recurrence, Local , Skin Neoplasms/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Dermatofibrosarcoma/pathology , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/etiology , Neoplasm, Residual , Retrospective Studies , Skin Neoplasms/pathology , Skin Transplantation , Surgical Flaps , Time Factors , Tumor Burden , Wound Closure Techniques , Young Adult
15.
JAMA Dermatol ; 152(9): 1008-14, 2016 09 01.
Article in English | MEDLINE | ID: mdl-27487033

ABSTRACT

IMPORTANCE: Whether the use of sterile vs nonsterile gloves in outpatient cutaneous procedures affects the rate of postoperative wound infection is unknown. OBJECTIVE: To explore rates of surgical site infection (SSI) with the use of sterile vs nonsterile gloves in outpatient cutaneous surgical procedures. DATA SOURCES: This systematic review and meta-analysis identified studies from Ovid MEDLINE (1946 to present), Ovid Cochrane Central Register of Controlled Trials (1991 to present), Ovid EMBASE (1988 to present), EBSCO Cumulative Index to Nursing and Allied Health Literature (1980 to present), Scopus (1996 to present), and Web of Science (1975 to present). STUDY SELECTION: Studies with information on sterile vs nonsterile gloves in outpatient surgical procedures were retrieved. Only randomized clinical trials and comparative studies were included for final analysis. DATA EXTRACTION: Data of trial design, surgery characteristics, and outcomes from published manuscripts and unpublished data were independently extracted. MAIN OUTCOMES AND MEASURES: Randomized clinical trials were considered high quality if randomization, allocation concealment, blinding, and follow-up completeness were appropriate. Relative risk and 95% CIs were derived for postoperative wound infections. RESULTS: Fourteen articles met eligibility and inclusion criteria for systematic review; they included 12 275 unique patients who had undergone 12 275 unique outpatient procedures with sterile or nonsterile gloves and had follow-up regarding SSI. With the exclusion of 1 single-arm observational study of 1204 patients, 11 071 patients from 13 studies remained in the meta-analysis. Of these, 228 patients were documented as having postoperative SSI (2.1%), including 107 of 5031 patients in the nonsterile glove group (2.1%) and 121 of 6040 patients in the sterile glove group (2.0%). Overall relative risk for SSI with nonsterile glove use was 1.06 (95% CI, 0.81-1.39). CONCLUSIONS AND RELEVANCE: No difference was found in the rate of postoperative SSI between outpatient surgical procedures performed with sterile vs nonsterile gloves.


Subject(s)
Dermatologic Surgical Procedures/adverse effects , Gloves, Surgical , Oral Surgical Procedures/adverse effects , Sterilization , Surgical Wound Infection/epidemiology , Dentistry , Dermatologic Surgical Procedures/instrumentation , Humans , Oral Surgical Procedures/instrumentation , Surgical Wound Infection/etiology
16.
Dermatol Surg ; 42(2): 167-75, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26771682

ABSTRACT

BACKGROUND: Mohs micrographic surgery (MMS) with frozen section immunohistochemistry is a treatment option for malignant melanoma in situ (MMIS) and lentigo maligna melanoma (LMM). Melan-A is a cytoplasmic melanocyte immunostain useful on frozen sections but may lack specificity. Microphthalmia transcription factor (MITF) is a more specific nuclear melanocyte immunostain less frequently used in MMS. OBJECTIVE: To quantify melanocyte density in chronic sun-damaged skin (CSDS), negative margin, and tumor from patients undergoing MMS for MMIS and LMM using MITF and melan-A. METHODS: Sixteen patients with MMIS or LMM had frozen sections from CSDS, negative margin, and 12 tumor samples, stained with MITF and melan-A. Melanocyte counts were performed. RESULTS: Chronic sun-damaged skin mean melanocyte count (MMC) for MITF and melan-A was 9.8 and 13.7, respectively, (p < .001). Negative margin MMC for MITF and melan-A was 8.84 and 14.06, respectively, (p < .001). Tumor MMC for MITF and melan-A was 63.5 and 62.4, respectively. CONCLUSION: Although both MITF and melan-A facilitate the identification of tumor during MMS for MMIS and LMM, the apparent melanocyte density on tumor-free CSDS appears higher with melan-A than MITF. Microphthalmia transcription factor provides a crisp outline of melanocyte nuclei and is a useful alternative stain to melan-A for MMS of melanoma.


Subject(s)
Carcinoma in Situ/surgery , Hutchinson's Melanotic Freckle/surgery , MART-1 Antigen/analysis , Melanoma/surgery , Microphthalmia-Associated Transcription Factor/analysis , Mohs Surgery/methods , Skin Neoplasms/surgery , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Carcinoma in Situ/pathology , Cell Count , Female , Frozen Sections , Humans , Hutchinson's Melanotic Freckle/pathology , Immunohistochemistry , Male , Melanocytes/pathology , Melanoma/pathology , Middle Aged , Skin Neoplasms/pathology
17.
Dermatol Surg ; 41(11): 1214-40, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26445288

ABSTRACT

BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in the United States. Cutaneous squamous cell carcinoma has an estimated incidence of more than 700,000 new cases per year and a 5% risk of metastasis. OBJECTIVE: To provide clinicians with guidelines for the management of cSCC based on evidence from a comprehensive literature review and consensus among the authors. MATERIALS AND METHODS: The authors conducted an extensive review of the medical literature on treatment methods for cSCC, taking into consideration cure rates, recurrence and metastatic rates, aesthetic and functional outcomes, and cost effectiveness of the procedures. RESULTS: Surgical treatments provide the best outcomes for cSCC. Mohs micrographic surgery is a cost-effective procedure that affords the highest cure rate, maximal tissue preservation, and superior cosmetic outcomes. Nonsurgical methods may be used as a primary treatment for low-risk squamous cell carcinomas, but the cure rates are lower. CONCLUSION: The cure rate remains the most important consideration in choosing the treatment method, but additional factors, such as the patient's general medical condition, psychosocial circumstances, the location of the tumor and cost effectiveness of the therapy should be considered. Mohs micrographic surgery remains the preferred treatment for high-risk tumors and tumors located in cosmetically sensitive areas.


Subject(s)
Carcinoma, Squamous Cell/therapy , Skin Neoplasms/therapy , Administration, Cutaneous , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/economics , Carcinoma, Squamous Cell/economics , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/pathology , Consensus , Cost-Benefit Analysis , Cryotherapy/economics , Evidence-Based Medicine , Humans , Immunocompromised Host , Incidence , Mohs Surgery/economics , Photochemotherapy/economics , Radiotherapy/economics , Risk Factors , Skin Neoplasms/economics , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Skin Neoplasms/pathology , United States/epidemiology
18.
Int J Dermatol ; 54(11): 1309-14, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26341946

ABSTRACT

BACKGROUND: Hailey-Hailey disease (HHD) is an autosomal dominant genodermatosis that leads to skin breakdown and blister formation, usually in intertriginous areas. Laser ablation is a known surgical treatment for HHD. OBJECTIVES: We report outcomes in a series of patients with HHD treated with carbon dioxide (CO2 ) laser ablation. METHODS: A retrospective chart review of data for 13 patients who underwent CO2 laser ablation for HHD was conducted. Questionnaires assessing effectiveness, pain, healing time, recurrence, new disease, complications, additional ablation, improvement in quality of life (QoL), and overall satisfaction were completed by all patients. RESULTS: All patients had been recalcitrant to previous treatments prior to CO2 laser ablation. Anatomic sites treated and anesthesia techniques for the procedure varied. The mean ± standard deviation (SD) score for the effectiveness of CO2 laser ablation for HHD was 9.3 ± 0.9 (maximum: 10). All patients reported improved QoL. No patient had recurring disease within the treatment field. Five patients underwent additional CO2 laser treatments at new sites. One patient reported postoperative infection. No other complications were identified. The mean ± SD score for overall satisfaction with CO2 laser ablation was 8.9 ± 1.1. CONCLUSIONS: Treatment with CO2 laser ablation is very effective and can lead to prolonged or permanent remission in most HHD patients. Patients are highly satisfied with the results and report a substantial improvement in QoL.


Subject(s)
Lasers, Gas/therapeutic use , Pemphigus, Benign Familial/surgery , Ablation Techniques/adverse effects , Adult , Carbon Dioxide , Female , Humans , Lasers, Gas/adverse effects , Male , Middle Aged , Pain, Postoperative/etiology , Patient Outcome Assessment , Patient Satisfaction , Quality of Life , Retreatment , Retrospective Studies , Treatment Outcome
19.
Dermatol Surg ; 41(10): 1122-5, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26356849

ABSTRACT

BACKGROUND: Melanoma in situ (MIS) diagnosed from a subtotal biopsy may be upstaged to invasive melanoma after resection. The frequency of this phenomenon is markedly variable. OBJECTIVE: To quantify the rate of upstaging MIS on the head and neck after resection at this institution, characterize the location of the invasive component relative to the clinically evident lesion, and determine the rate of upstaging with time. MATERIALS AND METHODS: The authors retrospectively reviewed clinical records of adult patients with a preoperative diagnosis of MIS on the head and neck from January 1994 to August 2012. Patient and tumor characteristics were recorded. RESULTS: In total, 624 patients met the inclusion criteria and 24 (4%) were upstaged after resection. Four patients had invasive disease beyond the clinically evident lesion. The annual percentage of upstaged lesions seemed to show an increasing trend with time. CONCLUSION: Upstaging of MIS on the head and neck occurs at a relatively low rate that may be increasing with time. Invasive components of lentigo maligna melanoma may exist beyond the clinically evident margins. Histological examination of the maximal amount of the surgical specimen is paramount for optimal staging and treatment of MIS.


Subject(s)
Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/surgery , Melanoma/pathology , Melanoma/surgery , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Adult , Aged , Female , Humans , Male , Middle Aged , Mohs Surgery , Neoplasm Invasiveness , Neoplasm Staging , Retrospective Studies , Melanoma, Cutaneous Malignant
20.
Dermatol Surg ; 41(7): 784-93, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26057410

ABSTRACT

BACKGROUND: Anticoagulant medications to date are not associated with increased risk of severe life-threatening complications during cutaneous surgery. Dabigatran and rivaroxaban are new orally administered anticoagulants that do not require laboratory monitoring and have no available specific antidotes, making perioperative management more complex. To the authors' knowledge, published data on the use of dabigatran or rivaroxaban in patients undergoing cutaneous surgery are limited. OBJECTIVE: The authors sought to study perioperative complications associated with dabigatran and rivaroxaban during cutaneous surgery. MATERIALS AND METHODS: Retrospective chart analysis was performed for all patients who underwent Mohs micrographic surgery or basic excision while taking dabigatran or rivaroxaban between January 1, 2010, and September 1, 2013, at Mayo Clinic, Rochester, MN. RESULTS: Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing. Four patients on rivaroxaban underwent 5 cutaneous surgeries without complication. CONCLUSION: Because no patients on dabigatran or rivaroxaban experienced severe hemorrhagic complications during cutaneous surgery, a strategy of continuing these medically necessary medications during cutaneous surgery seems reasonable.


Subject(s)
Antithrombins/adverse effects , Benzimidazoles/adverse effects , Dermatologic Surgical Procedures , Factor Xa Inhibitors/adverse effects , Hemorrhage/chemically induced , Morpholines/adverse effects , Skin Diseases/surgery , Thiophenes/adverse effects , beta-Alanine/analogs & derivatives , Administration, Oral , Aged , Antithrombins/administration & dosage , Benzimidazoles/administration & dosage , Dabigatran , Factor Xa Inhibitors/administration & dosage , Female , Hemorrhage/epidemiology , Humans , Male , Minnesota/epidemiology , Mohs Surgery , Morpholines/administration & dosage , Retrospective Studies , Risk Factors , Rivaroxaban , Thiophenes/administration & dosage , beta-Alanine/administration & dosage , beta-Alanine/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...